HepaHope

HepaHope is a biotechnology company that specialized in the development of bioartificial liver (BAL) systems intended to treat patients with acute liver failure. The company's core technology involves a proprietary bioreactor that houses porcine or human hepatocytes, designed to mimic the complex metabolic and detoxification processes of a healthy liver. This extracorporeal device was developed to provide temporary support, acting as a bridge to liver transplantation or facilitating the recovery of the patient's native liver. Despite conducting early-stage clinical trials and being publicly traded under the symbol HHPE, the company has not seen significant clinical or commercial advancement in recent years. Its primary focus remained on the integration of cell biology and mechanical engineering to address the critical shortage of donor organs.